TriSalus: 3 Key Takeaways for Long-Term Investors

On its third quarter of 2026 earnings call, held on Nov. 10, 2026, TriSalus (NASDAQ:TLSI) updated its full-year 2026 revenue guidance to $46 million to $48 million after reporting third-quarter revenue of $12.9 million. Sales team productivity delays and shifting treatment patterns disrupted short-term targets, testing management's ability to turn expanded clinical access into sustained growth. Three things management said stand out.

1. Sales Rep Productivity Lags in New Expansion Territories

Management doubled its sales force to capture a $2.5 billion market for pressure-enabled drug delivery (PEDD), a specialized catheter delivery system for liver tumors. New sales representatives in expansion territories required extra time to build physician relationships, causing third-quarter sales to miss internal targets.

Performance in our existing territories continue to grow and the shortfall relative to the plan in Q3 was concentrated in our new expansion territories, where new representatives are taking slightly longer than anticipated to reach full productivity.
-- Mary Szela, President and Chief Executive Officer

2. Regulatory Reimbursement Changes Expand Outpatient Facility Access

The Centers for Medicare and Medicaid Services (CMS), the federal agency governing healthcare reimbursement rates, finalized national pricing for outpatient procedures. This change gives the company a clear payment path across hospitals and an office-based lab (OBL), an outpatient clinical facility that offers faster patient scheduling.

Second, CMS established national pricing for G0577, the new code for PEDD embolization in the physician office setting, commonly referred to as an office-based lab or OBL at approximately $13,788 per procedure, up from approximately $12,300 in the proposed rule.
-- Mary Szela, President and Chief Executive Officer

3. New Product Clearance Unlocks Small Vessel Liver Procedures

A rapid shift toward treating small liver tumors required access to narrow blood vessels that existing catheters could not navigate. Federal regulators cleared TriNav Advance, allowing interventional radiologists to deliver targeted therapy into smaller vessels without altering their standard workflow.

With TriNav Advance, we now can address the full range of vessels encountered in liver embolization procedures. That means interventional radiologists can keep their preferred workflow while patients still benefit from PEDD.
-- Mary Szela, President and Chief Executive Officer

Looking Ahead

Manufacturing efficiencies elevated gross margin, the percentage of sales remaining after direct production costs. Commercial expansion into outpatient labs, rising sales representative productivity, and new device clearances support market expansion. Management monitors sales force execution and procedure adoption rates.

Gross margin for the quarter was 86% compared to 84% in the prior year period. The improvement was driven by lower average unit cost of TriNav and our commitment to continuous manufacturing improvements.
-- David Patience, Chief Financial Officer

The balance sheet maintains liquidity to fund commercial expansion plans without immediate capital raises.

We ended the quarter with approximately $41 million in cash, which we believe fully funds our strategic growth plan.
-- David Patience, Chief Financial Officer

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.